Biotech Values

[north40000]

Do you attribute the increased efficacy, OS, of the Keytruda/Pt chemo combination in patients having negative or no PD-L1[TPS=0 for PDL-1] to Keytruda or to the chemo portion of the combination used in therapy?

I gather we still have no data for RRRs in therapy using Keytruda alone, mono-therapy, in NSCLC that exceeds the expected 20-30% in targeted patients having PDL-1. Any side effects, sAEs, of the combination therapy I leave alone for now.